Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Sturge Weber Syndrome, Port-wine Mark

In brief

Primary Objective: • To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.

Key facts

Study ID

NCT01533376

Run by

Wills Eye

People needed

3

Starts

2012-02-01

Expected to finish

2019-02-01

Last updated by the study team

2019-03-21

Who can join

Age: 2 and older, up to 10. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age from 2 years to 10 years
• Port-Wine Mark
• English fluent and literate substitute decision maker
• Substitute decision maker vision sufficient to read informed consent document

You may not qualify if…

• Active ocular infection (conjunctivitis, keratitis,)
• History of systemic conditions including hypo/hypertension, hypoglycemia, bradycardia, asthma or any contraindication to beta blocker use
• Unable to comply with required follow-up
• Substitute decision maker not English fluent or not literate
• Substitute decision maker unable to read consent document
• Patient already using systemic beta-blocker or beta-agonist (Patients already using topical beta-blocker for glaucoma will not be excluded from study).

Where it is running

• Wills Eye Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.